Nicox (NICXF) Stock Price, News & Analysis

Company Overview

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis. ZERVIATE is marketed in the United States through a partnership with Bausch + Lomb, following its FDA approval and U.S. launch in 2021. In parallel, Nicox is advancing NCX 470, a nitric oxide–donating derivative of latanoprost, through Phase III trials for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox is also developing NCX 4251, an anti-inflammatory prodrug in Phase II development for the treatment of dry eye disease.

Established in 1996 and headquartered in Sophia Antipolis, France, Nicox maintains a presence in North America and Europe through its U.S. subsidiary and regional partnerships. The company has entered licensing agreements with Innova Pharma for ex-US distribution of ZERVIATE in select Eastern European markets, and continues to explore further collaborations to extend its commercial reach. Nicox’s research and development operations leverage both internal expertise and external alliances to accelerate the discovery of novel ocular therapies.

Nicox is led by Chief Executive Officer Antoine Millon, under whose leadership the company has executed multiple clinical milestones and strategic partnerships. With a management team experienced in ophthalmology drug development and commercialization, Nicox is positioned to advance its portfolio of differentiated candidates toward regulatory approvals and market entry. The company’s ongoing focus remains on delivering therapies that improve patient outcomes and address global needs in eye care.

Key Stats

• Today's Range: $0.30 to $0.30
• 50-Day Range: $0.30 to $0.30
• 52-Week Range: $0.25 to $0.30
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $20.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Nicox Stock Analysis - MarketRank™

Nicox scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nicox has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Nicox has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -6.67%

Earnings Growth

Earnings for Nicox are expected to decrease by -6.67% in the coming year, from $0.15 to $0.14 per share.

Price to Book Value per Share Ratio

Nicox has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Nicox has been sold short.

Short Interest Ratio / Days to Cover

Nicox has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nicox does not currently pay a dividend.

Dividend Growth

Nicox does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.84

News Sentiment

Nicox has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Nicox this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nicox insiders have not sold or bought any company stock.

Percentage Held by Institutions

Nicox has minimal institutional ownership at this time.

Company Calendar

• Today: 6/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NICXF
• Previous Symbol: NASDAQ:NICXF
• CIK: N/A
• Web: www.nicox.com
• Phone: (349) 724-5300
• Fax: 33-4-97-24-53-99
• Employees: 28
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.59 million
• Price / Sales: 5.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.05 per share
• Price / Book: 6.00

Miscellaneous

• Outstanding Shares: 68,920,000
• Free Float: N/A
• Market Cap: $20.68 million
• Optionable: Not Optionable
• Beta: -0.03